Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Poster presentation

Protective role of interferon gamma in murine antigen-induced arthritis

Authors: M Hückel, I Irmler, J Simon, A Radbruch, A Scheffold, R Bräuer

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

In human rheumatoid arthritis interactions of immune cells with resident cells, especially synovial fibroblasts, play a crucial role in the perpetuation of inflammatory and destructive processes in affected joints. Apart from macrophages, Th cells are predominant in cell infiltrates, and Th cell responses are specified as Th1 type. As interferon gamma (IFN-γ) secreting Th1 cells are suspected to promote autoimmune diseases, there is the notion that a shift of a Th1 response towards a Th2 response might ameliorate arthritis. However, in different models and therapy studies conflicting results are described. Thus, we investigated the role of IFN-γ in murine antigen-induced arthritis (AIA), a model with homologies to human rheumatoid arthritis in terms of histopathology, chronicity and responses to several immunomodulatory drugs. …
Metadata
Title
Protective role of interferon gamma in murine antigen-induced arthritis
Authors
M Hückel
I Irmler
J Simon
A Radbruch
A Scheffold
R Bräuer
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1395

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine